LEO Pharma and ICON Enter a Strategic Partnership to Propel Clinical Trial Execution Within Medical Dermatology
10 Março 2023 - 4:00AM
Business Wire
LEO Pharma, a global leader in medical dermatology, and ICON plc
(NASDAQ: ICLR) today announced a strategic partnership that
will enable LEO Pharma to scale clinical trial execution that is
patient-centric and cost effective, and which will support the
company’s overall ambition of building one of the most effective
and efficient clinical portfolio execution organisations in the
industry.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20230309005472/en/
The mission of the partnership is to improve the lives of
dermatology patients with access to innovative clinical trials and
the launch of new medicines. The partnership will operate under the
acronym of PACE, reflecting the requirement to move quickly to
address today’s clinical development challenges. It also represents
LEO Pharma and ICON’s shared values of Passion,
Agility, Communication and Excellence in
delivery.
Building on earlier collaboration successes within psoriasis
trials, LEO Pharma expects to further strengthen its transformation
journey by entering a strategic partnership with ICON. The
partnership will leverage both fully outsourced and functional
outsourcing models in a tailored and flexible hybrid approach. LEO
Pharma plans to achieve the following while remaining a patient
centric company:
- Drive efficiencies in clinical trials
- Significant and lean scalability in all areas of expertise
within clinical development
- Co-investment within the area of decentralised clinical
trials
- Access to a significant number of ICON in-house ancillary
services
- Economies of scope and scale
- Access to external data, knowledge & expertise as well as
technologies
- A partnership with a company that shares similar core
values
“We’ve been exploring several outsourcing models but found a
hybrid sourcing model to be the most efficient. Partnering with
ICON supports our 2030 strategy as it will help us to bring
innovative treatments to patients faster while also supporting a
more sustainable business through scalability and flexibility,”
said J�rg M�ller, Executive Vice President and head of Global
R&D at LEO Pharma. “ICON’s wealth of services and leading
position in clinical development will support LEO Pharma’s R&D
strategy building on driving innovation through partnerships and
support staying competitive.”
In supporting LEO Pharma through this partnership, ICON will
draw upon a team of over 500 professionals from across its business
to deliver tailored solutions, bringing differentiating and
enabling capabilities including its laboratories, Accellacare
site-network, FIRECREST site management and decentralised clinical
trial capabilities to create strategic advantage in how the trials
are delivered.
“ICON is delighted to enter this partnership with LEO Pharma
that truly takes advantage of our breadth of capability and
expertise. We take a flexible and integrated approach when working
with our partners, utilising fully outsourced, hybrid and FSP
models that complement our partner’s internal capabilities and
enable them to achieve their strategic goals. It is also motivating
for our employees to be working with a partner that shares our
values and has a commitment to improving the lives of patients,”
said Steve Cutler, CEO, ICON.
Ends
Additional Information
Connect with ICON on LinkedIn:
www.linkedin.com/company/icon-plc-2/ Follow @ICON_plc on Twitter:
https://twitter.com/iconplc Connect with LEO Pharma on LinkedIn:
www.linkedin.com/company/leo-pharma
About ICON plc
ICON is a world-leading healthcare intelligence and clinical
research organisation. From molecule to medicine, we advance
clinical research providing outsourced development and
commercialisation services to pharmaceutical, biotechnology,
medical device and government and public health organisations. We
develop new innovations, drive emerging therapies forward and
improve patient lives. With headquarters in Dublin, Ireland, ICON
employed approximately 41,100 employees in 111 locations in 53
countries as at December 31, 2022. For further information about
ICON, visit: www.iconplc.com.
About LEO Pharma
LEO Pharma is a global company dedicated to advancing the
standard of care for the benefit of people with skin conditions,
their families and society. Founded in 1908 and majority owned by
the LEO Foundation, LEO Pharma has devoted decades of research and
development to advance the science of dermatology, and today, the
company offers a wide range of therapies for all disease
severities. LEO Pharma is headquartered in Denmark with a global
team of 4,700 people, serving millions of patients across the
world. In 2022, the company generated net sales of DKK 10.6
billion.
ICON/ICLR-G
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230309005472/en/
Claire Quinn ICON +353 87 4066091 claire.quinn@iconplc.com
Pia Beltrao Hansen LEO Pharma +45 3140 1245
IRQDK@leo-pharma.com
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024